Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.
Actively Recruiting
This trial is focused on adults aged 50 and older with mild to moderate Alzheimers disease. Researchers aim to evaluate the safety and tolerability of Zunveyl, a medication taken orally, during 12 weeks of routine use. The study also looks at how the drug affects neuropsychiatric symptoms and caregiver distress for these patients. Participants will take Zunveyl delayed-release tablets twice daily, starting with 5 mg from Weeks 1 to 4, then increasing to 10 mg twice daily from Weeks 5 to 12. This open-label, phase 4 study monitors participants throughout this 12-week treatment period to assess how well they tolerate the medication and to observe any side effects. During the study, participants and their caregivers will attend regular visits where assessments will be made including safety checks, neuropsychiatric evaluations using the Neuropsychiatric Inventory NPI-12, and measurements of caregiver distress. Researchers will track adverse events, treatment interruptions, dose reductions, and overall tolerability scores up to Week 17. The total participation lasts about 12 weeks with follow-up assessments to evaluate ongoing safety and effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.